News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Moderna shares rose nearly 20% after Science Day, driven partly by a short squeeze, while its mRNA pipeline beyond vaccines faces a multi-year path to revenue.
Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.
Comcast created a stir among communication services stocks with a plan to spin off its media and entertainment assets into a new publicly traded company.
Moderna hit a 52-week high after it unveiled a strategy to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and AI-driven R&D.
Moderna stock soars on positive updates during the Science Day presentation. Jefferies sees significant further upside in MRNA shares.
The Morning Bull - US Market Morning Update Monday, Jun, 29 2026 US stock futures are pointing lower this morning, with E-mini S&P 500 contracts down about 0.3% and Nasdaq-100 futures weaker by roughly 1.2%, as investors weigh solid US spending against stubborn inflation. Core PCE inflation sits at 3.4% year over year, which means the cost of living is still rising faster than the Federal Reserve would like, while real personal spending grew 0.3% and incomes rose 0.7% in May. This suggests...
Moderna stock is up 125.51% in 2026, driven by an FDA flu vaccine win, a corporate pivot, and an expanding pipeline.
Cancer was a key focus, with programs targeting solid tumors, Lynch syndrome, melanoma, and non-small cell lung cancer.
Investor interest has focused on companies nearing key milestones, signing major partnerships, or improving their business outlook.
<body><p>STORY: U.S. stocks ended marginally lower on Friday, with the Dow and S&P 500 each shedding less than a tenth of a percent, and the Nasdaq losing about a quarter of a percent.</p><p>AI-related chip stocks suffered steep declines as some investors worry that the massive spending to build AI data centers may take too long to pay off.</p><p>Robert Conzo is CEO and managing director of The Wealth Alliance.</p><p>"The AI ship, although we love the technology, everyone loves the idea, it's like a cruise ship where the captain knows where they're going, the passengers don't know where this is going, passengers get nervous. The captain is the CEOs of these companies, putting billions and billions and billions of dollars of infrastructure into the AI. The market is the passengers saying, 'When are we going to be profitable here? At what point does profitability come to play?' Analysts are saying 2030, could be longer. And when prices go up, up, up, up higher, suddenly you start to question that value."</p><p>A report that OpenAI was considering delaying its public debut until next year also weighed on risk sentiment related to AI stocks.</p><p>:: Apple</p><p>Elsewhere in the market, shares of Apple rallied more than 3% and partly rebounded from a selloff a day earlier. The tech giant on Thursday raised iPad and MacBook prices, blaming soaring memory and storage chip costs.</p><p>:: Archive</p><p>Shares of ON Semiconductor tumbled almost 24% after the company agreed to acquire chip maker Synaptics in an all-stock deal valued at about $7 billion. Shares of Synaptics dipped more than 3.5%.</p><p>:: Moderna</p><p>On the flipside, shares of Moderna surged almost 13% to their highest level since 2024 after the drug developer hosted an investor event and showcased its pipeline.</p></body>
US equity indexes were lower on Friday amid a sell-off in technology stocks and despite a decline in
Stocks took an early hit on news that ChatGPT parent OpenAI might push its public offering to 2027, and a midday recovery faded into the close.
Yahoo Finance's Jared Blikre takes a closer look at some of Friday's trending tickers and stories, including Moderna (MRNA), Netflix (NFLX), and ON Semiconductor (ON).
Moderna shares were up more than 10% Friday after the biotech company revealed a new effort to make a treatment for autoimmune disorders and outlined several experimental drug projects that could help it diversify beyond Covid-19 vaccines in coming years.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Shares of Moderna (NASDAQ:MRNA) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer. Intraday, MRNA stock hit a new 52-week high of $69.29. The rally easily outpaces peer vaccine makers. Merck (NYSE:MRK) stock is up 2% to $128, while Pfizer (NYSE:PFE) stock trades up 2% ... Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?
Moderna shares pace toward their highest close since late 2024 after unveiling a new cell therapy program.
June 26 (Reuters) - Futures tied to the tech-heavy Nasdaq led Wall Street losses on Friday, as chip stocks came under renewed pressure after a sharp rally in the previous session, while some megacap
It's not just a "pandemic stock," after all.
The FDA’s Vaccines and Related Biological Products Advisory Committee has unanimously backed Moderna’s mRNA-based flu shot, mFlusiva, for adults 50 and older, after phase 3 data showed it to be about 27% more effective than a standard flu vaccine. This endorsement positions Moderna’s mRNA platform for a potential second major commercial use beyond COVID-19, expanding its role in routine respiratory vaccination for older adults. We’ll now explore how this unanimous FDA panel support for...
Moderna (MRNA) closed at $61 in the latest trading session, marking a +2.79% move from the prior day.
Shares of the vaccine maker have been on a hot streak, most recently catalyzed by a positive update from the FDA.
The panel unanimously said that the benefits of Moderna's mRNA jab outweigh its risks in preventing influenza in certain age groups.
The company's pending vaccine approvals could help the stock continue its rise.